JP4963765B2 - 臨床的に重要な真菌病原体を検出するための核酸プローブおよび方法 - Google Patents
臨床的に重要な真菌病原体を検出するための核酸プローブおよび方法 Download PDFInfo
- Publication number
- JP4963765B2 JP4963765B2 JP2001500809A JP2001500809A JP4963765B2 JP 4963765 B2 JP4963765 B2 JP 4963765B2 JP 2001500809 A JP2001500809 A JP 2001500809A JP 2001500809 A JP2001500809 A JP 2001500809A JP 4963765 B2 JP4963765 B2 JP 4963765B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- species
- candida
- fungal
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 115
- 244000053095 fungal pathogen Species 0.000 title claims description 33
- 108020004711 Nucleic Acid Probes Proteins 0.000 title description 5
- 239000002853 nucleic acid probe Substances 0.000 title description 5
- 239000000523 sample Substances 0.000 claims description 234
- 108091023242 Internal transcribed spacer Proteins 0.000 claims description 124
- 238000009396 hybridization Methods 0.000 claims description 103
- 241000894007 species Species 0.000 claims description 78
- 238000001514 detection method Methods 0.000 claims description 64
- 150000007523 nucleic acids Chemical class 0.000 claims description 60
- 108020004707 nucleic acids Proteins 0.000 claims description 58
- 102000039446 nucleic acids Human genes 0.000 claims description 58
- 230000002538 fungal effect Effects 0.000 claims description 50
- 241000222122 Candida albicans Species 0.000 claims description 40
- 210000004369 blood Anatomy 0.000 claims description 35
- 239000008280 blood Substances 0.000 claims description 35
- 238000003556 assay Methods 0.000 claims description 26
- 108091034117 Oligonucleotide Proteins 0.000 claims description 18
- 229940095731 candida albicans Drugs 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 16
- 241000222178 Candida tropicalis Species 0.000 claims description 15
- 201000007336 Cryptococcosis Diseases 0.000 claims description 15
- 101100213970 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ypt3 gene Proteins 0.000 claims description 15
- 241000144583 Candida dubliniensis Species 0.000 claims description 14
- 241000222173 Candida parapsilosis Species 0.000 claims description 12
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 12
- 239000002751 oligonucleotide probe Substances 0.000 claims description 12
- 125000006850 spacer group Chemical group 0.000 claims description 12
- 238000013518 transcription Methods 0.000 claims description 11
- 230000035897 transcription Effects 0.000 claims description 11
- 239000011324 bead Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 101100073099 Schizosaccharomyces pombe (strain 972 / ATCC 24843) its3 gene Proteins 0.000 claims description 5
- 241000222126 [Candida] glabrata Species 0.000 claims description 5
- 208000032343 candida glabrata infection Diseases 0.000 claims description 5
- 229940055022 candida parapsilosis Drugs 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 5
- 239000008188 pellet Substances 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 239000012139 lysis buffer Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- 238000003260 vortexing Methods 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 40
- 230000003321 amplification Effects 0.000 description 36
- 238000003199 nucleic acid amplification method Methods 0.000 description 36
- 241000228212 Aspergillus Species 0.000 description 27
- 125000003729 nucleotide group Chemical group 0.000 description 26
- 239000002773 nucleotide Substances 0.000 description 25
- 241001225321 Aspergillus fumigatus Species 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 208000031888 Mycoses Diseases 0.000 description 19
- 241000233872 Pneumocystis carinii Species 0.000 description 19
- 206010017533 Fungal infection Diseases 0.000 description 16
- 230000035945 sensitivity Effects 0.000 description 16
- 108091093088 Amplicon Proteins 0.000 description 14
- 241000233866 Fungi Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 241001527609 Cryptococcus Species 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000030507 AIDS Diseases 0.000 description 12
- 241000228197 Aspergillus flavus Species 0.000 description 12
- 241000235645 Pichia kudriavzevii Species 0.000 description 12
- 244000197813 Camelina sativa Species 0.000 description 11
- 241000351920 Aspergillus nidulans Species 0.000 description 10
- 238000012408 PCR amplification Methods 0.000 description 10
- 206010036790 Productive cough Diseases 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 238000005194 fractionation Methods 0.000 description 10
- 210000003802 sputum Anatomy 0.000 description 10
- 208000024794 sputum Diseases 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 108700022487 rRNA Genes Proteins 0.000 description 9
- 206010007134 Candida infections Diseases 0.000 description 8
- 244000285963 Kluyveromyces fragilis Species 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 201000003984 candidiasis Diseases 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 201000009085 invasive aspergillosis Diseases 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 241000203233 Aspergillus versicolor Species 0.000 description 7
- 239000003298 DNA probe Substances 0.000 description 7
- 206010061598 Immunodeficiency Diseases 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108020000949 Fungal DNA Proteins 0.000 description 6
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 201000000317 pneumocystosis Diseases 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940091771 aspergillus fumigatus Drugs 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000011895 specific detection Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 201000002909 Aspergillosis Diseases 0.000 description 4
- 208000036641 Aspergillus infections Diseases 0.000 description 4
- 101150041258 CALB2 gene Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108020004565 5.8S Ribosomal RNA Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108020001027 Ribosomal DNA Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 3
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101150092532 CALB1 gene Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000581002 Murex Species 0.000 description 2
- 108010010677 Phosphodiesterase I Proteins 0.000 description 2
- 206010067565 Pneumonia cryptococcal Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 101150036851 S100g gene Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000009640 blood culture Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000003771 laboratory diagnosis Methods 0.000 description 2
- 238000012092 latex agglutination test Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005497 microtitration Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 206010052366 systemic mycosis Diseases 0.000 description 2
- OQJGZGAYSCWFCK-UHFFFAOYSA-N 2-[4-(furan-2-ylmethyl)-5-[[4-methyl-3-(trifluoromethyl)phenyl]methylsulfanyl]-1,2,4-triazol-3-yl]pyridine Chemical compound C1=C(C(F)(F)F)C(C)=CC=C1CSC(N1CC=2OC=CC=2)=NN=C1C1=CC=CC=N1 OQJGZGAYSCWFCK-UHFFFAOYSA-N 0.000 description 1
- 208000012124 AIDS-related disease Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 238000002768 Kirby-Bauer method Methods 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 101100025911 Mus musculus Ncoa3 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000235056 Pichia norvegensis Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000223231 Trichosporon beigelii Species 0.000 description 1
- 241000082085 Verticillium <Phyllachorales> Species 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 241000509563 [Candida] inconspicua Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- -1 alkyl phosphorothioates Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000017773 candidemia Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009862 superficial mycosis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99870109.8 | 1999-05-28 | ||
| EP99870109 | 1999-05-28 | ||
| US13862199P | 1999-06-11 | 1999-06-11 | |
| US60/138,621 | 1999-06-11 | ||
| PCT/EP2000/004714 WO2000073499A2 (en) | 1999-05-28 | 2000-05-24 | Nucleic acid probes and methods for detecting clinically important fungal pathogens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012014151A Division JP2012120535A (ja) | 1999-05-28 | 2012-01-26 | 臨床的に重要な真菌病原体を検出するための核酸プローブおよび方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003501049A JP2003501049A (ja) | 2003-01-14 |
| JP2003501049A5 JP2003501049A5 (enExample) | 2012-03-15 |
| JP4963765B2 true JP4963765B2 (ja) | 2012-06-27 |
Family
ID=46506639
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001500809A Expired - Lifetime JP4963765B2 (ja) | 1999-05-28 | 2000-05-24 | 臨床的に重要な真菌病原体を検出するための核酸プローブおよび方法 |
| JP2012014151A Pending JP2012120535A (ja) | 1999-05-28 | 2012-01-26 | 臨床的に重要な真菌病原体を検出するための核酸プローブおよび方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012014151A Pending JP2012120535A (ja) | 1999-05-28 | 2012-01-26 | 臨床的に重要な真菌病原体を検出するための核酸プローブおよび方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6858387B1 (enExample) |
| EP (1) | EP1185702B1 (enExample) |
| JP (2) | JP4963765B2 (enExample) |
| AU (1) | AU782305B2 (enExample) |
| CA (1) | CA2374878C (enExample) |
| ES (1) | ES2621547T3 (enExample) |
| WO (1) | WO2000073499A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4963765B2 (ja) * | 1999-05-28 | 2012-06-27 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 臨床的に重要な真菌病原体を検出するための核酸プローブおよび方法 |
| WO2001083821A2 (en) * | 2000-05-01 | 2001-11-08 | Gen-Probe Incorporated | Polynucleotide probes for detection and quantitation of candida species |
| WO2002079512A2 (en) * | 2001-03-29 | 2002-10-10 | University Of Nevada - Las Vegas | Method for detection and quantification of the fungus aspergillus fumigatus using quantitative pcr |
| WO2003080866A1 (en) * | 2002-03-26 | 2003-10-02 | Council Of Scientific And Industrial Research | Novel primers for identifying aflatoxinogenic aspergilli and an improved use thereof |
| JP4377810B2 (ja) | 2002-05-17 | 2009-12-02 | アメリカ合衆国 | アスペルギルス種の分子的同定方法 |
| JP2004290171A (ja) * | 2003-02-07 | 2004-10-21 | Akira Hiraishi | 微生物の分子生物学的同定技術 |
| EP1690938A1 (de) * | 2005-02-11 | 2006-08-16 | Qiagen GmbH | Verfahren zur Isolierung von Nukleinsäuren, wobei die Nukleinsäuren bei erhöhter Temperatur an einer Matrix immobilisiert werden |
| US20100311041A1 (en) | 2005-06-14 | 2010-12-09 | Statens Serum Institut | Pcr diagnostics of dermatophytes and other pathogenic fungi |
| US20070050311A1 (en) * | 2005-08-30 | 2007-03-01 | Caterpillar Inc. | Assembly should cost application |
| EP1945810B1 (en) * | 2005-09-20 | 2015-07-01 | AdvanDx, Inc. | Reagents, methods and kits for classification of fungi and direction of anti-fungal therapy |
| JP2007159411A (ja) | 2005-12-09 | 2007-06-28 | Canon Inc | プローブセット、プローブ固定担体及び遺伝子検査方法 |
| WO2007101664A2 (de) * | 2006-03-08 | 2007-09-13 | Fungus Bioscience Gmbh | Verbesserter aspergillosetest in klinischen proben |
| RU2348695C2 (ru) | 2006-05-23 | 2009-03-10 | Закрытое акционерное общество "Молекулярно-медицинские технологии" | Дифференцирующий и специфический олигонуклеотиды для идентификации последовательностей днк инфекционных агентов в биологических материалах, способ видовой идентификации инфекционных агентов, биочип и набор для осуществления этого способа |
| JP5015518B2 (ja) * | 2006-08-04 | 2012-08-29 | 東洋鋼鈑株式会社 | ハウスダストアレルギーの原因となるダニ・カビ類の検出・識別用マイクロアレイ |
| PT103729A (pt) * | 2007-05-04 | 2008-11-04 | Stab Vida Investigacao E Servi | Estojo e processo para a detecção e identificação de leveduras de interesse clínico, através de uma amplificação isotérmica de adn seguida de hibridação com oligonucleótidos específicos, e respectivas utilizações. |
| JP5196847B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
| JP5196850B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
| JP5196843B2 (ja) | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
| JP5317430B2 (ja) * | 2007-05-14 | 2013-10-16 | キヤノン株式会社 | プローブセット、プローブ担体、及び真菌の判別同定方法 |
| JP5196866B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
| JP5196845B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
| JP5196846B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体、検査方法及びdna検出用キット |
| JP5196856B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
| JP5196861B2 (ja) | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
| JP5196853B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
| JP5196859B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体、検査方法及びdna検出用キット |
| JP5196865B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
| JP5196860B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
| JP5196858B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体、検査方法及びdna検出用キット |
| JP5196854B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
| US7829735B2 (en) * | 2007-10-26 | 2010-11-09 | Northwestern University | Universal phosphoramidite for preparation of modified biomolecules and surfaces |
| CA2715991A1 (en) | 2007-12-26 | 2009-07-09 | Gen-Probe Incorporated | Amplification oligomers and methods to detect candida albicans 26s rrna or encoding dna |
| CA2720292A1 (en) * | 2008-04-01 | 2009-10-08 | Metametrix Clinical Laboratory | Process and method for monitoring gastrointestinal microbiota |
| ES2335179B1 (es) * | 2008-09-19 | 2011-09-14 | Instituto De Salud Carlos Iii | Metodo para la deteccion simultanea de histoplasma capsulatum y paracoccidioides brasiliensis. |
| MX352246B (es) | 2009-03-18 | 2017-10-25 | Instituto Potosino De Investig Cientifica Y Tecnologica A C | Metodo in vitro para la deteccion de candida glabrata, kit de diagnostico y usos de los mismos. |
| PL2536850T3 (pl) | 2010-02-15 | 2017-09-29 | Council Of Scientific & Industrial Research | Sposób wykrywania patogenów grzybiczych |
| US10214780B2 (en) | 2012-03-09 | 2019-02-26 | City University Of Hong Kong | Method and means for identification of animal species |
| EP2636753B1 (en) * | 2012-03-09 | 2018-07-25 | City University of Hong Kong | Method and means for identification of animal species |
| US10253353B2 (en) * | 2013-12-06 | 2019-04-09 | The Broad Institute, Inc. | Enhanced methods of ribonucleic acid hybridization |
| CN105420372A (zh) * | 2015-12-17 | 2016-03-23 | 安徽出入境检验检疫局检验检疫技术中心 | 检测梨黑斑病菌的pcr引物以及使用该引物的检测方法 |
| CN107130015B (zh) * | 2016-02-29 | 2023-07-11 | 上海翔琼生物技术有限公司 | 一种检测烟曲霉菌的荧光定量pcr试剂盒 |
| CN106497796A (zh) * | 2016-07-20 | 2017-03-15 | 辽宁省微生物科学研究院 | 一种食用菌菌种的单克隆高效选育方法 |
| CN112626263B (zh) * | 2021-01-20 | 2022-08-05 | 中国人民解放军总医院 | 酶切探针恒温检测呼吸道感染真菌病原体的试剂盒 |
| CN112941231A (zh) * | 2021-04-26 | 2021-06-11 | 南方海洋科学与工程广东省实验室(湛江) | 一种用于白色念珠菌检测的探针、方法及应用 |
| EP4577673A1 (en) * | 2022-08-26 | 2025-07-02 | Denka Company Limited | Methods for the detection and identification of fungal species |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998011257A1 (en) * | 1996-09-16 | 1998-03-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Centers for Disease Control and Prevention, Technology Transfer Office | Methods and compositions for the detection of candida spp. |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US546027A (en) * | 1895-09-10 | Edgar charles parker | ||
| US4617102A (en) * | 1985-03-21 | 1986-10-14 | Lifecodes Corp. | Process and apparatus for purifying and concentrating DNA from crude mixtures containing DNA |
| US5541308A (en) * | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
| AU7429591A (en) * | 1990-04-18 | 1991-10-24 | Gene-Trak Systems | Nucleic acid probes for the detection of giardia lamblia |
| DE69332202T2 (de) | 1992-05-18 | 2003-05-28 | Richard David Cannon | Methoden zur diagnose von pilzinfektionen |
| US5426027A (en) | 1993-05-20 | 1995-06-20 | The Government Of The United States Of America As Represented By The Secretary | Nucleic acid probes and methods for detecting Candida DNA cells in blood |
| US6017699A (en) * | 1993-09-15 | 2000-01-25 | The University Of Pittsburgh | PCR identification and quantification of important Candida species |
| US5585238A (en) * | 1994-04-25 | 1996-12-17 | Ciba-Geigy Corporation | Detection of fungal pathogens using the polymerase chain reaction |
| US5763169A (en) * | 1995-01-13 | 1998-06-09 | Chiron Diagnostics Corporation | Nucleic acid probes for the detection and identification of fungi |
| US5693501A (en) | 1995-03-08 | 1997-12-02 | Indiana University Advanced Research & Technology Institute | Compounds and methods to determine presence of Histoplasma capsulatum |
| EP0846186B1 (de) | 1995-08-17 | 2008-02-20 | Myconostica Limited | Extraktion, amplifikation und sequentielle hybridisierung von pilzzellen-dna sowie verfahren zum nachweisen von pilzzellen in klinischem material |
| FR2749011B1 (fr) | 1996-03-22 | 1998-08-28 | Univ Claude Bernard Lyon | Sonde, sequence nucleiques et procede notamment, de detection et d'identification de levures, de meme que les outils genetiques correspondants |
| US5874221A (en) | 1996-08-28 | 1999-02-23 | The United States Of America As Represented By The Secretary Of Agriculture | Species specific method for the PCR detection of phythophthora |
| US5814453A (en) | 1996-10-15 | 1998-09-29 | Novartis Finance Corporation | Detection of fungal pathogens using the polymerase chain reaction |
| US5800997A (en) | 1996-11-01 | 1998-09-01 | Novartis Finance Corporation | Detection of maize fungal pathogens using the polymerase chain reaction |
| ATE320506T1 (de) * | 1997-05-02 | 2006-04-15 | Us Gov Health & Human Serv | Nukleinsäuren zur erkennung von aspergillus spezien |
| US6242178B1 (en) * | 1997-07-30 | 2001-06-05 | Centers For Disease Control And Prevention | Nucleic acid probes for detecting Candida species |
| US5827695A (en) | 1997-08-04 | 1998-10-27 | Novartis Finance Corporation | Detection of wheat fungal pathogens using the polymerase chain reaction |
| US6080543A (en) | 1997-12-08 | 2000-06-27 | E. & J. Gallo Winery | Detection of fungal pathogens |
| JP4963765B2 (ja) * | 1999-05-28 | 2012-06-27 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 臨床的に重要な真菌病原体を検出するための核酸プローブおよび方法 |
-
2000
- 2000-05-24 JP JP2001500809A patent/JP4963765B2/ja not_active Expired - Lifetime
- 2000-05-24 WO PCT/EP2000/004714 patent/WO2000073499A2/en not_active Ceased
- 2000-05-24 AU AU55255/00A patent/AU782305B2/en not_active Ceased
- 2000-05-24 CA CA2374878A patent/CA2374878C/en not_active Expired - Lifetime
- 2000-05-24 EP EP00940266.0A patent/EP1185702B1/en not_active Expired - Lifetime
- 2000-05-24 ES ES00940266.0T patent/ES2621547T3/es not_active Expired - Lifetime
- 2000-09-15 US US09/662,462 patent/US6858387B1/en not_active Expired - Lifetime
-
2004
- 2004-10-19 US US10/967,254 patent/US7741461B2/en not_active Expired - Fee Related
-
2012
- 2012-01-26 JP JP2012014151A patent/JP2012120535A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998011257A1 (en) * | 1996-09-16 | 1998-03-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Centers for Disease Control and Prevention, Technology Transfer Office | Methods and compositions for the detection of candida spp. |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1185702B1 (en) | 2017-02-08 |
| ES2621547T3 (es) | 2017-07-04 |
| US20050164243A1 (en) | 2005-07-28 |
| CA2374878C (en) | 2014-10-14 |
| JP2012120535A (ja) | 2012-06-28 |
| WO2000073499A2 (en) | 2000-12-07 |
| WO2000073499A3 (en) | 2001-08-09 |
| US6858387B1 (en) | 2005-02-22 |
| EP1185702A2 (en) | 2002-03-13 |
| JP2003501049A (ja) | 2003-01-14 |
| AU5525500A (en) | 2000-12-18 |
| AU782305B2 (en) | 2005-07-21 |
| CA2374878A1 (en) | 2000-12-07 |
| US7741461B2 (en) | 2010-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4963765B2 (ja) | 臨床的に重要な真菌病原体を検出するための核酸プローブおよび方法 | |
| US6372430B1 (en) | Nucleic acids for detecting Aspergillus species and other filamentous fungi | |
| JP2002504817A (ja) | 真菌の検出および同定のための核酸プローブ | |
| US7871779B2 (en) | Molecular identification of Aspergillus species | |
| TW200907057A (en) | A novel method for simultaneous detection and discrimination of bacterial, fungal, parasitic and viral infections of eye and central nervous system | |
| EP1945812B1 (en) | Compositions and methods for the detection of candida species | |
| Meletiadis et al. | Evaluation of a polymerase chain reaction reverse hybridization line probe assay for the detection and identification of medically important fungi in bronchoalveolar lavage fluids | |
| JP5621992B2 (ja) | カンジダ種を検出および同定するための方法 | |
| Arancia et al. | Construction and use of PCR primers from a 70 kDa heat shock protein gene for identification ofCandida albicans | |
| JP2002142775A (ja) | カンジダ属真菌検出用核酸及びそれを用いたカンジダ属真菌の検出方法 | |
| Rodriguez-Villalobos et al. | Cross reaction between a pan-Candida genus probe and Fusarium spp. in a fatal case of Fusarium oxysporum pneumonia | |
| Rossau et al. | Development of a PCR-Based Line Probe | |
| JP2002142774A (ja) | 真菌検出用核酸及びそれを用いた真菌の検出方法 | |
| WO2010061347A1 (en) | Pcr based diagnostic method for the identification of clinically important candida species | |
| Racil et al. | Species-Specific Identification of a Wide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20061003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20061003 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070524 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100316 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100616 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100623 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100716 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100726 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100813 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100820 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100915 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110726 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111026 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111102 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111115 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111122 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20120126 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120228 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120327 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4963765 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150406 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |